ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 0935

Effects of Ixekizumab Treatment on Structural Changes in the Sacroiliac Joints Based on MRI Assessments at 16 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis

Walter Maksymowych1, Xenofon Baraliakos2, Robert Lambert3, Robert Landewé4, David Sandoval Calderon5, Hilde Carlier6, Jeffrey Lisse7, Xiaoqi Li5, Maja Hojnik5 and Mikkel Ostergaard8, 1Department of Medicine, Division of Rheumatology at the University of Alberta, Alberta, Canada, 2Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 3University of Alberta, Edmonton, AB, Canada, 4Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, 5Eli Lilly and Company, Indianapolis, IN, 6Eli Lilly and Company, Brussels, Belgium, 7Eli Lilly and Company, Tucson, AZ, 8Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark

Meeting: ACR Convergence 2021

Keywords:

Session Information

Date: Sunday, November 7, 2021

Title: Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: To evaluate the effect of treatment with ixekizumab versus placebo (PBO) on structural lesions in the sacroiliac joints (SIJ) at 16 weeks in patients with non-radiographic axial spondyloarthritis (nr-axSpA).

Methods: Patients with active nr-axSpA who were biologic-naïve (COAST-X, NCT02757352) were randomized 1:1:1 to receive double-blinded ixekizumab 80 mg every 4 (Q4W) or 2 weeks (Q2W) with an 80-mg or 160-mg starting dose at week 0 or PBO. SIJ magnetic resonance imaging (MRI) was assessed by Spondyloarthritis Research Consortium of Canada (SPARCC) SIJ structural score (SSS). Treatment comparisons used analysis of covariance based on observed cases.

Results: Of 303 randomized patients, 266 patients (Q4W: n=85, Q2W: n=91, PBO: n=90) with an MRI scan available at baseline and week 16 were included in this analysis. Mean SPARCC SSS for PBO and ixekizumab dose groups were similar at baseline (Figure 1 and Table). Significant reduction in SPARCC SSS for erosion was observed in both ixekizumab dose groups versus PBO (Fig. 1A). Increased erosion scores occurred for fewer patients in both ixekizumab dose groups versus PBO (Fig. 1B). Decreased erosion scores occurred for more patients in both ixekizumab dose groups versus PBO (Fig. 1B). Mean change from baseline in SPARCC SSS was significantly greater for ixekizumab for fat metaplasia (Q4W) and backfill (Q4W and Q2W) versus PBO (Table). Changes in ankylosis were generally not observed (Table).

Conclusion: Treatment with ixekizumab versus PBO led to significant reductions in erosions and significant increases in fat metaplasia and backfill in the SIJ in patients with nr-axSpA assessed at 16 weeks of treatment.

Disclosures: W. Maksymowych, Abbvie, 2, 5, 6, BMS, 2, 5, Boehringer Ingelheim, 2, Celgene, 2, Eli Lilly and Company, 2, 5, Galapagos, 2, 5, Janssen, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, UCB, 2, 5, 6; X. Baraliakos, AbbVie, 2, 5, 6, Chugai, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, UCB, 2, 5, 6, Bristol-Myers Squibb, 2, 5, 6, Celegene, 2, 5, 6, Merck, 2, 6, Werfen, 2; R. Lambert, Pfizer, 2; R. Landewé, AbbVie, 5, 6, Novartis, 5, 6, Pfizer, 5, 6, UCB, 5, 6, Astra-Zeneca, 6, Bristol Myers Squibb, 6, Celgene, 6, Eli-Lilly, 6, Janssen, 6, Gilead, 6, Galapagos, 6, Glaxo-Smith-Kline, 6; D. Sandoval Calderon, Eli Lilly and Company, 3; H. Carlier, Eli Lilly and Company, 3; J. Lisse, Eli Lilly and Company, 3, 11; X. Li, Eli Lilly and Company, 3; M. Hojnik, Eli Lilly and Company, 3; M. Ostergaard, AbbVie, 2, 5, 6, Bristol-Myers Squibb, 2, 6, Celgene, 2, 6, Novartis, 2, 5, 6, Boehringer Ingelheim, 2, 6, Eli Lilly, 2, 6, Hospira, 2, 6, Janssen, 2, 6, Merck, 2, 5, 6, Novo, 2, 6, Orion, 2, 6, Pfizer Inc, 2, 6, Regeneron, 2, 6, Roche, 2, 6, UCB, 2, 6, GSK, 2, 6, Mundipharma, 2, 6, Schering-Plough, 2, 6, Takeda, 2, 6, Wyeth, 2, 6, Centocor, 2, 5, 6.

To cite this abstract in AMA style:

Maksymowych W, Baraliakos X, Lambert R, Landewé R, Sandoval Calderon D, Carlier H, Lisse J, Li X, Hojnik M, Ostergaard M. Effects of Ixekizumab Treatment on Structural Changes in the Sacroiliac Joints Based on MRI Assessments at 16 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/effects-of-ixekizumab-treatment-on-structural-changes-in-the-sacroiliac-joints-based-on-mri-assessments-at-16-weeks-in-patients-with-non-radiographic-axial-spondyloarthritis/. Accessed .

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effects-of-ixekizumab-treatment-on-structural-changes-in-the-sacroiliac-joints-based-on-mri-assessments-at-16-weeks-in-patients-with-non-radiographic-axial-spondyloarthritis/